Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Employees - 4, CEO - Adi Zuloff-Shani, Sector - Healthcare, Country - CA, Market Cap -

Altman ZScore(max is 10): -8.7, Piotroski Score(max is 10): 1, Working Capital: $2143751, Total Assets: $5180456, Retained Earnings: $-25878290, EBIT: -4993200, Total Liabilities: $2878986, Revenue: $0

AryaFin Target Price - $1.1 - Current Price $ - Analyst Target Price $